重组人甲状旁腺激素对慢性甲状旁腺功能减退症成人健康相关生活质量的影响
这项多国随机安慰剂对照研究纳入122例慢性甲状旁腺功能减退症成人,在优化钙和活性维生素D补充剂使血清钙达目标水平后,随机接受安慰剂(n=39)或rhPTH(1-84)(n=83,起始50 μg/d,可滴定至100 μg/d)。第24周时组间差异未达统计学显著,但rhPTH(1-84)组较基线在躯体成分汇总评分(P=0.004)、躯体疼痛(P<0.05)、总体健康(P<0.05)和活力(P<0.001)方面有显著改善,安慰剂组各领域无显著变化。
要点
- rhPTH(1-84)组较基线在躯体成分汇总评分(P=0.004)、躯体疼痛(P<0.05)、总体健康(P<0.05)、活力(P<0.001)有显著改善。
- 安慰剂组各SF-36领域较基线均无显著变化。
- SF-36评分0至24周变化幅度与基线评分呈负相关,基线HRQoL较低者更可能从治疗中获益。
核心结论
- rhPTH(1-84)治疗可能改善慢性甲状旁腺功能减退症成人的健康相关生活质量。
研究设计与样本
- 多国、随机、安慰剂对照研究,纳入122例慢性甲状旁腺功能减退症成人,随机分为安慰剂组(n=39)和rhPTH(1-84)组(n=83)。
- 经优化期调整钙和/或活性维生素D补充剂使血清钙达目标水平(8.0至9.0 mg/dL;2.0至2.2 mmol/L)后随机分组,rhPTH(1-84)起始剂量50 μg/d,可滴定至100 μg/d,并调整补充剂剂量维持目标血清钙水平。
- 主要结局为从基线(优化后、随机化时)至第24周SF-36评估的HRQoL变化。
主要发现
- 总体组间差异未达统计学显著。
- rhPTH(1-84)组较基线在躯体成分汇总评分(P=0.004)、躯体疼痛(P<0.05)、总体健康(P<0.05)和活力(P<0.001)领域有显著改善。
- 安慰剂组各领域较基线均无显著变化。
- SF-36评分0至24周变化幅度与基线评分呈负相关,基线HRQoL较低的患者更可能对治疗出现改善。
关键数值与推荐
- 目标血清钙水平为8.0至9.0 mg/dL(2.0至2.2 mmol/L)。
- rhPTH(1-84)起始剂量50 μg/d,可滴定至100 μg/d。
- rhPTH(1-84)组躯体成分汇总评分较基线改善P=0.004,躯体疼痛P<0.05,总体健康P<0.05,活力P<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Reduced health-related quality of life (HRQoL) is common in patients with hypoparathyroidism treated conventionally with calcium and active vitamin D supplements. OBJECTIVE: To examine the effects of recombinant human parathyroid hormone [rhPTH(1-84)] on HRQoL as measured by the 36-Item Short-Form Health Survey (SF-36) during a multinational, randomized, placebo-controlled study. PATIENTS: Adults (N = 122) with chronic hypoparathyroidism. INTERVENTION(S): After an optimization period when calcium and/or active vitamin D supplements were adjusted to reach target serum calcium levels (8.0 to 9.0 mg/dL; 2.0 to 2.2 mmol/L), patients were randomly assigned to receive placebo (n = 39) or rhPTH(1-84) (n = 83) (starting dose, 50 μg/d, could be titrated up to 100 μg/d); supplement doses were adjusted to maintain target serum calcium levels. MAIN OUTCOME MEASURE(S): Change from baseline (postoptimization, at randomization) to week 24 in HRQoL as assessed by the SF-36. RESULTS: Overall, the between-group differences were not statistically significant. However, in the rhPTH(1-84) group, there were significant improvements in the physical component summary score (P = 0.004), and in body pain (P < 0.05), general health (P < 0.05), and vitality (P < 0.001) domains as compared with baseline values. In the placebo group, there were no significant changes for any domains. The magnitude of change between 0 and 24 weeks in SF-36 scores was negatively correlated with baseline scores, such that patients with lower HRQoL at baseline were more likely to experience improvement in response to treatment. CONCLUSION: Treatment with rhPTH(1-84) may improve HRQoL in adults with hypoparathyroidism.
引用
- Vokes TJ, Mannstadt M, Levine MA, et al. Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. J Clin Endocrinol Metab. 2018. PMID: 29099947. doi:10.1210/jc.2017-01471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。